ASSESSING THE COST-UTILITY OF ETELCALCETIDE: A MARKOV MODEL

被引：0
|
作者：
Stollenwerk, B. [1 ]
Iannazzo, S. [2 ]
Akehurst, R. [3 ]
Adena, M. [4 ]
Briggs, A. [5 ]
Dehmel, B. [6 ]
Parfrey, P. [7 ]
Belozeroff, V [6 ]
机构：
[1] Amgen Europe GmbH, Zug, Switzerland
[2] SIHS SRL, Turin, Italy
[3] BresMed Hlth Solut, Sheffield, S Yorkshire, England
[4] Datalyt Pty Ltd, Bruce, ACT, Australia
[5] Univ Glasgow, Glasgow, Lanark, Scotland
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Mem Univ, St John, NF, Canada
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PUK18
引用
收藏
页码：A519 / A519
页数：1
相关论文
共 50 条
  • [41] Cost-utility Analysis of Screening for Diabetic Retinopathy in Japan: A Probabilistic Markov Modeling Study
    Kawasaki, Ryo
    Akune, Yoko
    Hiratsuka, Yoshimune
    Fukuhara, Shunichi
    Yamada, Masakazu
    OPHTHALMIC EPIDEMIOLOGY, 2015, 22 (01) : 4 - 12
  • [42] EVOLUTION OF A COST-UTILITY MODEL OF DONEPEZIL FOR ALZHEIMER'S DISEASE
    Peters, Jaime L.
    Anderson, Rob
    Hoyle, Martin
    Hyde, Chris
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2013, 29 (02) : 147 - 154
  • [43] The QALY model: Utilities for cost-utility analysis in health care
    Fryback, DG
    DECISION SCIENCE AND TECHNOLOGY: REFLECTIONS ON THE CONTRIBUTIONS OF WARD EDWARDS, 1999, : 331 - 351
  • [44] Prenatal Screening for CMV Primary Infection: A Cost-Utility Model
    El Hachem, Gebrael
    Poder, Thomas G.
    Carey, Catherine Mc
    Gantt, Soren
    Kakkar, Fatima
    Sab, Marc
    Renaud, Christian
    Boucoiran, Isabelle
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2025, 132 (06) : 805 - 815
  • [45] COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL
    Nguyen, C. M.
    Mendes, M.
    Bounthavong, M.
    Christopher, M.
    Morreale, A. P.
    VALUE IN HEALTH, 2010, 13 (03) : A127 - A128
  • [46] Cost-utility analysis using a Markov model to compare prescription statins versus potential over the counter statins in USA
    Gandhi, P. K.
    McGhan, W. F.
    Peterson, A. M.
    VALUE IN HEALTH, 2006, 9 (06) : A352 - A352
  • [47] Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model
    Patel, Jignesh J.
    Mendes, Margaret A. S.
    Bounthavong, Mark
    Christopher, Melissa L. D.
    Boggie, Daniel
    Morreale, Anthony P.
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2012, 18 (02) : 247 - 255
  • [48] COST-UTILITY OF CANCER THERAPIES - THE 'COST' OF DIFFERENT UTILITY GENERATION STRATEGIES
    Meads, D. M.
    McCabe, C.
    Hulme, C. T.
    Edlin, R.
    Kharroubi, S. A.
    Browne, C.
    Ford, H.
    Dunn, J.
    Marshall, A.
    VALUE IN HEALTH, 2014, 17 (07) : A327 - A327
  • [49] Cost-utility analysis of screening program for diabetic retinopathy in Japan: a probabilistic Markov modeling study
    Kawasaki, Ryo
    Akune, Yoko
    Hiratsuka, Yoshimune
    Yamada, Masakazu
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [50] Management of Incidentally Detected Barrett's in a Young Person: a Markov Process Cost-Utility Analysis
    Boardman, Charles
    Sonnenberg, Amnon
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S607 - S608
12345